Skip to main content
. 2019 Mar 25;23(5):3151–3165. doi: 10.1111/jcmm.14148

Figure 7.

Figure 7

The atractylenolide I, atractylenolide II and atractylenolide III were compared regarding their sensitivity to chemo drugs. A, The structure drawing of atractylenolide I, atractylenolide II and atractylenolide III. B, The atractylenolide I, atractylenolide II and atractylenolide III at the concentrations of 0, 12.5, 25, 50, 100 and 200 μg/mL were assessed regarding their impacts on the viability of colorectal cancer cells. *P < 0.05 when compared with atractylenolide II. C, The atractylenolide II at the concentrations of 0, 12.5, 25, 50, 100 and 200 μg/mL was assessed concerning its contributions to the viability of colorectal cancer cells at the time‐points of post‐treatment 24, 48 and 72 h. *P < 0.05 when compared with the 48 h. D, The atractylenolide II was compared regarding its acting on the sensitivity of colorectal cancer cells in response to 5‐fluorouracil, mitomycin, cisplatin and adriamycin were compared. *P < 0.05 when compared with NC